Subscribe To
FSTX / F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Content Topics
Star
Therapeutics
Merger
Arbitrage
Opportunity
Expected
F star
Therapeutics
Stock
FSTX
FSTX News
By Seeking Alpha
January 28, 2023
F-star's Delayed Acquisition Presents A Risky Opportunity
FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national secur more_horizontal
By Seeking Alpha
July 29, 2022
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the o more_horizontal
By Zacks Investment Research
May 3, 2022
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prep more_horizontal
By Seeking Alpha
March 14, 2022
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript more_horizontal
By GlobeNewsWire
March 2, 2022
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biophar more_horizontal
By GlobeNewsWire
March 2, 2022
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biophar more_horizontal
By GlobeNewsWire
March 2, 2022
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biophar more_horizontal
By Seeking Alpha
January 27, 2022
F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
The company's unique selling proposition is its novel, tetravalent bispecific antibody platform which has earned validation through partnership deals more_horizontal